Elliot Backer, MD
Pulmonary Disease · Lebanon, NHNPI 1336407113
Payments from drug & device makers
What this record shows
This record is dominated by education: $16,000 of the $23,810 with a category attached, or 67.2%. Intuitive Surgical accounts for 81.4% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $10,233, more than ten times the $518 reported in 2019. Among pulmonary disease clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 54 payments — averaging $440.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$19K
- Covidien LP$2K
- Boston Scientific$999
- Johnson & Johnson$615
- ERBE USA Inc$146
- AstraZeneca$128
- plus $89 from 3 others
What the payments were for
- Speaking & faculty fees$1,0004%
- Travel & lodging$4,25318%
- Food & beverage$2,55611%
- Education$16,00067%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 22 | $19,376 |
| Covidien LP | 9 | $2,458 |
| Boston Scientific | 7 | $999 |
| Johnson & Johnson | 9 | $615 |
| ERBE USA Inc | 1 | $146 |
| AstraZeneca | 2 | $128 |
| Steris Corporation | 1 | $38 |
| Olympus Corporation Of The Americas | 1 | $26 |
| Bayer | 2 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$19,297
- superDimension$2,130
- GENERAL - THERAPIES$620
- Monarch Platform$324
- VIO 300 D$146
- APC2$146
- CRYO$146
How this compares
$23,810 in reported general payments places this provider in the 90th percentile of 78 pulmonary disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $8,603 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,346 |
| Prednisone | 21 | $105 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Lebanon
- Donald MahlerLebanon$411K
- Jeffrey StewartLebanon$30K
- Erik SwensonLebanon$29K
- H ParkerLebanon$13K
- Alex GiffordLebanon$8K
- Peter DelongLebanon$4K
- William WeissLebanon$1K
- John HoweLebanon$631
- John NuschkeLebanon$477
- James LeiterLebanon$77
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.